Zobrazeno 1 - 8
of 8
pro vyhledávání: '"JL Vinent Genestar"'
Autor:
MA Romo Murillo, R Farré Riba, M Sánchez Celma, JL Vinent Genestar, JM Català Foguet, M Villaronga Flaqué, D Gavrus Ion, JA Cuartero Lozano, A Diaz Cambron, F Bossacoma Busquets
Publikováno v:
Section 5: Patient Safety and Quality Assurance.
Background Oral liquid medicines, such as solutions and suspensions, are commonly given to young children, because they are easy to swallow and allow weight-based dosage. The development of oral medicines for paediatric patients often requires age-ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b368b93e59f06b5809e3bd80142ea80a
https://doi.org/10.1136/ejhpharm-2019-eahpconf.527
https://doi.org/10.1136/ejhpharm-2019-eahpconf.527
Autor:
JL Vinent Genestar, J Arrojo Suárez, A Martínez Deyà, L Alsina Manrique de Lara, F Bossacoma Busquets, M Pallares Borras, AD Madrid Aris, A Comes Escoda, M Sánchez Celma
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Rituximab is a monoclonal antibody directed against the CD20 antigen, expressed on the surface of B-lymphocytes, promoting the lyses of the cells. It is labelled for adult different indications, non-Hodgkin’s lymphoma, chronic lymphocyti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab7d383efba93a232596a0aa54c4a0ba
https://doi.org/10.1136/ejhpharm-2019-eahpconf.339
https://doi.org/10.1136/ejhpharm-2019-eahpconf.339
Autor:
A Ruiz Llobet, F Bossacoma Busquets, A Comes, VP Celis Passini, M Sácnhez Celma, JL Vinent Genestar, J Arrojo Suárez, N Arranz Pasqual
Publikováno v:
Eur J Hosp Pharm
Background Approved therapeutic indications for human normal immunoglobulin (HNIg) in the paediatric population are: primary immunodeficiency syndromes, hypogammaglobulinaemia post-stem cell transplantation, AIDS with recurrent infections and primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31968e1020c088b378a1c9a610a24276
https://europepmc.org/articles/PMC7535465/
https://europepmc.org/articles/PMC7535465/
Autor:
V Santa-María López, P Montoliu Alcón, A Comes Escoda, M Sánchez Celma, JL Vinent Genestar, M Villaronga Flaqué, F Bossacoma Busquets, J Arrojo Suárez
Publikováno v:
Eur J Hosp Pharm
Background Bevacizumab is a humanised monoclonal antibody against vascular endothelial growth factor authorised for adult cancer treatments. There are several case series and clinical trials on the use of bevacizumab in paediatric tumours at dose ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0c4f9645b09152631c869a3a6f86481
https://europepmc.org/articles/PMC7535719/
https://europepmc.org/articles/PMC7535719/
Publikováno v:
Eur J Hosp Pharm
Background Human normal immunoglobulins (HNIg) have multiple indications such as replacement therapy or as immunomodulatory therapy for several autoimmune disorders. The use of HNIg in cancer patients is controversial, especially in children. Since H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3385fde380dc97b4451316a4edcbfa73
https://doi.org/10.1136/ejhpharm-2018-eahpconf.406
https://doi.org/10.1136/ejhpharm-2018-eahpconf.406
Autor:
A Comes Escoda, H Hernández Salvador, F Bossacoma Busquets, M Sánchez Celma, JL Vinent Genestar, J Arrojo Suárez
Publikováno v:
Drug information and pharmacotherapy.
Background The MAPK pathway is a signal transduction cascade involved in the uncontrolled proliferation of many human cancers. A number of studies have shown that this pathway is constitutively activated in a high proportion of paediatric low grade g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12a234f1be27abde624dea5eb1e9413e
https://doi.org/10.1136/ejhpharm-2017-000640.289
https://doi.org/10.1136/ejhpharm-2017-000640.289
Autor:
Jm, Llop Talaverón, Berlana David, Mb, Badía Tahull, Fort Casamartina E, Jl, Vinent Genestar, Tubau Mola M, Jódar Massanés R
Publikováno v:
Europe PubMed Central
Binary and ternary parenteral nutrition preparations may be of limited use in certain cases. The goal of this study is to establish difficult nutritional situations to handle and analyze the type of formula used in these situations.The study included
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e8d2578b392ebf6efcfb461efb472e88
https://pubmed.ncbi.nlm.nih.gov/15315114
https://pubmed.ncbi.nlm.nih.gov/15315114
Autor:
Llop Talaverón JM; Unidad de Nutrición Parenteral, Servicio de Farmacia, Ciudad Sanitaria y Universitaria de Bellvitge, L'Hospitalet de Llobregat, Barcelona. josep.llop@csub.scs.es, Berlana Martín D, Badía Tahull MB, Fort Casamartina E, Vinent Genestar JL, Tubau Mola M, Jódar Massanés R
Publikováno v:
Nutricion hospitalaria [Nutr Hosp] 2004 Jul-Aug; Vol. 19 (4), pp. 229-35.